Friday, 29 March 2024


RaQualia, Interprotein to research on pain drug

04 February 2013 | News | By BioSpectrum Bureau

Good news for patients suffering from pain - RaQualia Pharma and Interprotein enter into collaborative pain research agreement

Good news for patients suffering from pain - RaQualia Pharma and Interprotein enter into collaborative pain research agreement

Singapore: RaQualia Pharma and Interprotein entered into a collaborative research agreement. The partnership will focus on drug discovery research for a specific protein-protein interaction (PPI) inhibitor in the disease domain of pain. 

Under the agreement, RaQualia and Interprotein will collaborate to identify new drug candidates, combining RaQualia's core expertise in drug discovery and development, and Interprotein's platform technology, Intendd, on in-silico screening of PPI inhibitors.

Interprotein will be eligible to receive upfront payment, contingency payment and further research milestones from RaQualia under the agreement. RaQualia will be eligible to receive the world-wide exclusive rights of all results from this collaborative research.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account